INTRODUCTION
The complement system is a major contributor to humoral immunity, mediating many activities that contribute to host defense and opsonization for phagocytosis. More than 30 proteins, both in serum and on cell surfaces are part of this system (Kang et al., 2009 ). Complement recognizes a wide range of targets including microorganisms, altered host cells and synthetic particles. Targets are recognized by proteins of the three activation pathways, C1q from the classical pathway, Mannan binding lectin (MBL) and ficolins from the lectin pathway and C3, factors H and B and properdin from the alternative pathway. Complement activation by the classical pathway occurs when the first component of complement, C1, binds, mainly via charge interactions (Roumenina et al., 2007) to immune complexes (containing IgG or IgM) or directly to a non-immunoglobulin target surface. The antibody-independent activation of C1 has been described for a wide variety of organisms and substances (Sim and Malhotra, 1994) including DNA (Agnello et al., 1969) , Gram-negative bacteria (Clas et al., 1989) , retroviruses (Cooper et al., 1976) , amyloids and prions , anionic phospholipids (Marjan et al., 1994) and synthetic materials (Rybak-Smith et al., 2010) . C1 is a complex of three glycoproteins, C1q, C1r and C1s. C1r and C1s are proteases which are activated when C1q binds to a target. Complement activation by the alternative pathway occurs when C3, factor B and properdin interact with particulate matter such as bacterial and fungal cell wall constituents, IgG immune complexes, or a wide variety of other compounds and surfaces (Sim and Malhotra, 1994 ). Conversely, complement factor H binding to surfaces and/or to C3b on surfaces inhibits activation of the alternative pathway (Carreno et al., 1989) . MBL and ficolins, serum proteins with structural similarity to C1q, bind mainly via nonionic interactions to glycans and other targets, leading to activation of the lectin pathway via the MBL-associated serine protease 2 (MASP-2) which is homologous to C1r and C1s (Wallis et al., 2010) .
Anionic phospholipids are known complement classical pathway activators (Chonn et al., 1991; Marjan et al., 1994; Tan and Sim, 2001) . Cardiolipin (CL), a negatively charged phospholipid found abundantly in mitochondrial membranes binds C1q and activates the classical pathway in an antibodyindependent manner (Kovacsovics et al., 1985) . C1q also binds to phosphatidylglycerol (PG), phosphatidylinositol (PI) and phosphatidylserine (PS) (Marjan et al., 1994; Tan et al., 2002; Païdassi et al., 2008) . However, in separate work, the complement downregulator, factor H, has also been shown to bind strongly to cardiolipin (Kertesz et al., 1995) , but its binding to other anionic phospholipids has not been investigated. Although C1q and factor H are not similar in structure, both bind mainly by charge interactions to a wide range of macromolecules.
C1q is a 460 kDa glycoprotein composed of 18 polypeptide chains (6A-C) and is present in human serum at a concentration of about 115 mg/L (Reid and Porter, 1976; Dillon et al., 2009 ). The A, B and C chains combine to form six equivalent subunits each consisting of a collagen-like "stalk" at the N terminus of the molecule and a carboxyl-terminal heterotrimeric globular (gC1q) domain. The six subunits associate to form a structure resembling a bunch of six tulips when viewed under the electron microscope. The C1r and C1s subcomponents of C1 bind the collagen region of C1q. Binding of C1q to ligands brings about a conformational change in the collagen region that activates C1r and C1s (Dodds et al., 1978) . C1q binds to IgG and IgM-containing immune complexes via its gC1q domains. Non-antibody ligands also bind generally but perhaps not exclusively via the gC1q domain (Tacnet-Delorme et al., 2001) .
Factor H, a single polypeptide chain protein of 155 kDa, is composed of 20 complement control protein (CCP) modules (Ripoche et al., 1988a) . Its concentration in human sera is reported to vary quite widely between individuals (150-750 mg/L: Charlesworth et al., 1979; Edey et al., 2009; Ingram et al., 2010) . It prevents the assembly of and dissociates the alternative complement pathway C3 convertase, C3bBb, and acts as a cofactor for factor I-mediated cleavage of C3b . The discrimination between activators and nonactivators of the alternative pathway is determined by binding of factor H to surfaces and to surface-associated C3b (Carreno et al., 1989 ). The interaction of factor H with surface charge clusters and C3b is of major importance in the activation and regulation of complement.
C1q represents a forward acting component as it serves to activate complement whereas factor H serves to downregulate complement activation. Here we examined the interactions of C1q and factor H with various phospholipids and their ability to activate the whole complement system. Using solid phase phospholipids (immobilised on microtiter wells) and multilamellar phospholipid liposomes, we found that both C1q and factor H bound to anionic phospholipids. The binding of immunoglobulins to phospholipid-coated wells had only small effects on the subsequent binding of C1q to phospholipids. The significance of C1q binding to phospholipids was demonstrated by the activation (consumption) of complement. Factor H was able to compete strongly with C1q for binding to CL, thus acting as a regulator of the activation of the classical pathway. Using purified recombinant globular head regions of the A, B and C chains of C1q, we found that each of the globular head chains contributed to the binding of C1q to phospholipids. . The wells were washed, and the amount of bound C1q or factor H was measured (in cpm/well). Binding to control wells (containing no phospholipids but blocked with ovalbumin) was negligible. Error bars represent standard deviation for five experiments. and very low binding to PC. Factor H bound to all the anionic phospholipids tested (Fig. 1) . Strong binding was observed to PA, CL, PG and PI with lesser binding to PS, and very low binding to neutral PE and PC. The quantity of C1q bound to CL was comparable to its binding to wells coated with 5 μg/well of rabbit IgG Fc fragment (not shown). To ensure that the differences detected in 125 I-C1q or 125 I-factor H binding ( Fig. 1) were not caused by differences in the amount of phospholipids adsorbed to the microtiter wells, we quantified (Stewart, 1980) Binding of proteins from whole human serum to CL-coated wells
RESULTS

Interaction
To identify other proteins in human serum which can bind to CL, human serum was loaded onto CL-coated wells on a 24 well plate and the bound proteins were analyzed by SDS-PAGE. As shown in Fig. 3A , there were two major components in the CL binding fractions together with some minor components. The major ones are β 2 -1 and factor H, as shown by their respective co-migration with a β 2 -1 and factor H standard under nonreducing ( Fig. 3A) and reducing (not shown) conditions. Their identities were also confirmed by N-terminal amino acid sequencing (not shown). C1q was found from its co-migration with a C1q standard (Fig. 3A) , and in these conditions, it bound in lower quantity than factor H or β 2 -1.
Inhibition of C1q binding to CL by factor H and β 2 -1
Purified β 2 -1 competes with purified factor H for binding to CL (Kertesz et al., 1995) and factor H and β 2 -1 are two of the major serum proteins binding to CL. We investigated whether factor H and β 2 -1 compete with C1q for binding to CL. As shown in Fig. 3B , both factor H and β 2 -1 potently inhibit the binding of 125 I-C1q to CL-coated wells. Factor H also competes with 125 I-C1q for binding to CL liposomes. This is consistent with the comparable binding of C1q and factor H to CL at saturation (Table 1) . These results (Fig. 3A and 3B) show that factor H and β 2 -1 compete with C1q in serum for binding to CL. A maximum of only~70% inhibition was observed at a 3:1 molar ratio of factor H or β 2 -1 to C1q. This ratio is however lower than the ratio in human sera, which for factor H:C1q is in the range about 6:1 up to about 30:1.
A previous report indicated that rheumatoid arthritic protein (RHP), which was characterized as being antigenically related to factor H, was able to bind to the gC1q domain of C1q (Holme et al., 1992) . In another report (EasterbrookSmith et al., 1992) , factor H was suggested to bind directly to C1q. Since factor H was able to compete with C1q for binding to CL (Fig. 3B) , we sought to clarify whether the effect of factor H in inhibiting C1q binding was due to the interaction of factor H with CL, or factor H interaction with C1q. (Fig. 4) . This difference could be attributed to added competition in NHS by the C1 complex (C1q-C1r 2 -C1s 2 ) in addition to the inhibition by factor H and β 2 -1, which are present in both NHS and C1q-depleted serum. These results further corroborated the observations from Fig. 3A where factor H and β 2 -1 were found to be the two major CL binding species with much smaller quantities of C1q binding. Factor H and β 2 -1 therefore competed with C1q in serum for binding to CL.
Binding of purified IgA, IgG or IgM to phospholipids and their effect on C1q binding to phospholipids
Immunoglobulins from serum bind to solid-phase anionic phospholipids: for example, CL-coated wells are used in clinical assays for measuring anti-phospholipid antibodies (Harris et al., 1987 (A) Human serum was added to the CL-coated wells and proteins that remained bound after thorough washing were analyzed by SDS-PAGE (9.5% w/v acrylamide gel under nonreducing conditions). Lane 1, molecular mass markers; lane 2, eluate from CL coated wells after incubation of pooled human serum for 2 h at RT in CL-coated wells; lane 3, human C1q standard; lane 4, human β 2 -1; lane 5, human factor H. The C1q standard shows the AB dimer at~55 kDa. The CC dimer is partially aggregated under these conditions (Reid and Porter, 1976) the maximum binding of C1q or factor H (365 fM/well; Table 1 ). Saturation binding of immunoglobulin required a very large input of total immunoglobulin, indicating that a very low proportion of total immunoglobulin from NHS would bind to phospholipid surfaces. The low binding to CL of immunoglobulin, relative to C1q and factor H was confirmed, as shown in Fig. 3A and in Table 1 .
Further experiments were carried out to determine whether the low quantity of immunoglobulin that bound to CL at saturation influenced the binding of sub-saturating quantities of C1q. A semiquantitative ELISA was used to explore the specificity of binding of the immunoglobulin, in contrast to the measurements of binding at saturation that were done using radioiodinated immunoglobulin. On phospholipid-coated wells, IgA (Fig. 5A) , IgG (Fig. 5B) and IgM (Fig. 5C ) all bound PA, CL, PS, PG, PI and PE. Only IgG showed significant binding to PC.
The effect of phospholipid-bound immunoglobulin on C1q binding to the phospholipid-coated wells was tested using 125 I-C1q ( Fig. 5D-F) . IgG had little effect on C1q binding (Fig. 5E ). This was as expected result since the quantity of IgG bound was very low (Table 1) . Furthermore, the IgG molecules were likely to be widely-spaced (the quantity of IgG shown in Table 1 would occupy only 0.01%-1.4% of the surface area of the well). IgM also had little effect on C1q binding (Fig. 5F ). C1q could bind either to the phospholipids or to the bound IgM. Assuming that the affinities of C1q for phospholipids and for IgM are similar, no difference in C1q Error bars represent standard deviation for three experiments. binding would be expected. For IgA, however, there appeared to be a consistent decrease in C1q binding (Fig. 5D ). Since the quantity of IgA bound in this experiment (Table 1) was only 1.2-6.4 fM which occupied less than 0.5% of the surface area of the wells, IgA was unlikely to inhibit C1q through simple steric interference. However, the maximum binding of immunoglobulin to the phospholipid-coated wells was low and the effect on binding of C1q was small. 
Complement activation in NHS by phospholipids
C1q can bind to a anionic phospholipids and immunoglobulin has little influence on the binding of C1q to phospholipids. Therefore, it was of interest to investigate if phospholipids or immunoglobulin-coated phospholipid wells were capable of activating complement using a classical pathway complement consumption assay. This was done with IgG-depleted serum to further minimise possible effects of antibodies. The ionic strength of the serum incubated with phospholipidcoated wells or phospholipids liposomes was approximately 110 mM (after diluting 1:1 with DGVB 2+ ) compared with earlier C1q direct binding assays to PL that were performed at a salt strength equivalent to 150 mM NaCl (VB 2+ ) (Fig. 1A ). Phospholipid-coated wells were incubated with (A) purified IgA (35.7 μg /well), (B) IgG (50 μg/well) or (C) IgM (30 μg/ well) in PBS-0.5mM EDTA for 1 h at RT and immunoglobulin binding was detected by use of appropriate affinity purified alkaline phosphatase-conjugated goat anti-human immunoglobulin heavy chain specific antibodies. Binding to the control wells (containing no phospholipids but blocked with ovalbumin) was negligible. The quantity of immunoglobulin used was well above the level required to achieve saturation binding (Table 1) . To examine the effect of phospholipid-bound immunoglobulin on the phospholipid binding of C1q, phospholipid-coated wells were pre-incubated with (D) IgA (35.7 μg/well), (E) IgG (18.5 μg/well) or (F) IgM (20 μg/well) for 1 h at RT and the wells were then washed. A fixed amount of 125 I-C1q (10 4 cpm/well) in VB 2+ was then added to all the immunoglobulincoated wells and incubated at RT for 1 h before washing the wells and quantifying the C1q bound. Relative binding is measured as cpm bound per well. Error bars represent standard deviation for five experiments.
Negatively-charged phospholipids were capable of consuming complement (Fig. 6A ). These included PA, CL, PS, PG and PI, all of which bear net negative charges at pH 7.4. PA and CL were more effective in consuming complement than PS, PG or PI. The neutral phospholipid, PE, could also consume complement to about the same extent as PS, PG and PI. In contrast, PC which is also net neutral at pH 7.4 failed to consume complement. Despite the low binding of immunoglobulin to phospholipid-coated wells (Table 1 ) and the small effect on C1q binding ( Fig. 5E and 5F), presaturation of the phospholipid-coated wells with IgM or IgG does increase complement consumption. The effect of IgM was large (nearly double the consumption with PI and PE). IgG also clearly stimulated complement consumption and IgA appeared to have a regular small positive effect. Since immunoglobulin exerted only small effects on C1q binding, the influence on complement consumption was likely to be at a later stage, for example, C4 fixation (Dodds and Porter, 1979) . We also wished to examine if the alternative complement pathway was activated (consumed) by phospholipid-coated wells. There was no consumption of the alternative pathway by the seven phospholipids tested (PA, CL, PS, PG, PI, PE and PC) (Fig. 6B) . The presence of bound IgG, but not IgM or IgA, stimulated very low complement consumption (4%-7%) in all the phospholipids tested except for PC where there was negligible consumption.
We examined using a classical pathway assay if phospholipid liposomes were able to consume complement. All five anionic phospholipid liposomes tested (PA, CL, PS, PG Figure 6 . Complement activation in pooled human serum by phospholipids. IgG-depleted human serum was incubated with various phospholipid-coated wells or phospholipid-coated wells pre-incubated with IgA (35.7 μg/well), IgG (18.5 μg /well) or IgM (20 μg /well) for 1 h at 37°C. (A) The effect of phospholipids on the consumption of total complement or (B) alternative complement pathway was determined by complement hemolytic assays and expressed as a percentage above the baseline consumption of complement in serum incubated in control wells which were not coated with phospholipids. Pooled human serum was also incubated with various multilamellar phospholipid liposomes (C) for 1 h at 37°C. The effect of phospholipid liposomes on the consumption of total complement was also determined by complement hemolytic assays and expressed as a percentage above the baseline consumption in serum incubated with no liposomes. Error bars represent standard deviation for five experiments. and PI) were able to consume complement ( Fig. 6C ) with CL showing the highest level of consumption. Neutral PE and PC liposomes did show very low consumption of complement.
Interaction of the recombinant forms of individual globular head regions of C1q with phospholipids
It has been proposed that C1q interaction with anionic phospholipids is surface charge dependent and it has been suggested it is not mediated by the globular heads (Bradley et al., 1999) . We investigated if the globular heads are responsible for binding to anionic phospholipids. Using purified recombinant globular head-MBP fusion proteins from the A, B and C chains of C1q, we investigated if the globular heads were able to bind phospholipids. I-ghC bound significantly to all the phospholipids tested except PC (Fig. 7A) . The ghC module could bind to PA, CL, PS, PG, PI and PE with the highest binding observed to PA and CL. There was negligible binding of ghC to PC-coated wells. Binding of ghB to all the phospholipids was lower than for ghC, Binding of ghA was low and quite similar for all phospholipids except PC. The binding of 125 I-ghA, 125 I-ghB and 125 I-ghC to PA and CL liposomes was also examined. All three globular head modules bound more to CL than to PA. ghA did not bind significantly to PA liposomes. The binding of individual globular head modules and whole C1q to immobilised phospholipids were qualitatively similar, except to PE ( Fig. 1 and 7A ). Native C1q had very high binding to PE-coated wells but not to PE liposomes (Fig. 2) . ghA, ghB and ghC showed moderate binding to PE-coated wells. It might be considered that since the recombinant heads bind less than native C1q, binding is mostly via the collagen region. However, PE-coated wells activate the classical pathway (Fig. 6A ) and therefore must bind C1, in which the collagen region is mostly sterically blocked by the presence of C1r and C1s. The binding to PE-coated wells therefore may partially involve interfaces between the globular regions of different chains, e.g., A:B or A:C interfaces, which are absent in these recombinant proteins. It is likely that binding of C1q to PE-coated wells is artifactual, in that C1q interacts with a structure on PE or a relative orientation of multiple PE molecules which does not form in liposomes.
The binding of globular head modules (Fig. 7B ) and whole C1q (Fig. 2) quantity of the ghA, ghB and ghC bound in Fig. 7 are different: ghC bound best and ghA least. Similarly, as shown in Fig. 8 , ghA was most readily competed out by whole C1q and ghC least readily. This may be caused by differences in the degree of oligomerisation of the ghA, ghB and ghC preparations. Gel filtration analysis (not shown) showed that the ghC contained more than 50% of material larger than trimers, ghB contained a small amount of aggregated material while ghA did not. In Fig. 7A and 7B, the results for PA and CL binding suggest that there may be some differential affinity of the different globular heads for PA and CL.
Inhibition of classical pathway activation by factor H
C1q binds by its globular heads to CL-coated wells, and this binding stimulates consumption of complement. Factor H competes with C1q for binding to CL, so factor H should inhibit classical pathway activation mediated by C1q. Since factor H, in its role as an alternative pathway downregulator, is known to affect C3 turnover, we could not use a complement activation test in which C3 turnover would influence the results. Therefore, we used C4 turnover, which precedes C3 activation, as a measure of classical pathway activation. A serum sample was depleted of C1q and factor H, and then the two proteins added back at different concentrations. The modified sera were incubated with CL-coated wells, and then the deposition of C4b was measured, as an indicator of the extent of classical pathway activation (Fig. 9) . As the molar ratio of factor H:C1q increases, the deposition of C4b decreases. This shows that factor H is effectively regulating classical pathway activation.
DISCUSSION
Although complement plays an important role in the body's resistance to infectious microoganisms, it is also central to the recognition and clearance of altered or damaged host cells (apoptotic and necrotic host cells). C1q has been found to bind to subcellular particles such as mitochondria (Peitsch et al., 1988) and chromatin (Sim and Malhotra, 1994) which are exposed during cell necrosis. Many studies implicate C1q Figure 9 . Influence of factor H concentration on C4 deposition on CL-coated wells. Samples of C1q and factor H-depleted serum were repleted with a constant amount of C1q and variable factor H and were incubated in CL-coated wells for 1 h at 37°C. Repletion was done by mixing 13 µL of depleted serum with 87 µL of VB 2+ containing 0.9 µg and 0.9-21.6 µg of factor H. One hundred microlitres of the repleted serum was diluted 1:1 with DGVB 2+ and added to wells and incubated at 37°C for 1 h. The CL-coated wells were washed and the amount of C4b deposition was determined as described in Materials and Methods. The control serum is C1q and factor H depleted with no repletion. Results of three experiments are averaged. in the uptake and clearance of apoptotic cells (Korb and Ahearn, 1997; Ogden et al., 2001 ). In the field of gene therapy and drug delivery systems, phospholipid liposomes have been shown to be recognized and cleared by complement (Szebeni, 1998) . Charge interactions are likely to be important in the complement-mediated recognition of targets, for example, with anionic phospholipids, which are exposed on altered host cells (apoptotic and necrotic). Several studies have shown C1q binding to anionic phospholipids (Kovacsovics et al., 1985; Bradley et al., 1999) but there have been only limited studies of factor H binding to phospholipids (Kertesz et al., 1995) . However, the binding of factor H to anionic surfaces for example, to synthetic polyanions has been explored (Carreno et al., 1989) . Therefore, it was of interest to examine how C1q, a forward acting component and factor H, a downregulator of complement interact with phospholipids. We examined the binding of the two proteins using solid-phase bound phospholipids and multilamellar phospholipid liposomes. 125 I-C1q ( Fig. 1) bound to all five anionic phospholipids:
PG, PI, PA, PS and CL. Surprisingly, however, the highest binding was to the non-anionic PE. Binding to PC was negligible. When 125 I-C1q binding to phospholipids in liposomes was examined (Fig. 2) , binding to all the anionic phospholipids was again observed, but there was no binding to PE liposomes. This strongly suggests that the binding of C1q to well-bound PE is an in vitro artifact involving forms of PE oriented differently from those that are exposed when PE is in a bilayer membrane. There was very high binding of 125 IC1q to CL liposomes, while binding to PA, PS, PG and PI liposomes was lower, but above the level of the PC control.
It has been proposed that the binding of several nonimmunoglobulin targets, including CL liposomes, by C1q was through the collagen region (Jiang et al., 1992 (Jiang et al., , 1994 Bradley et al., 1999) . In the present study, recombinant forms of globular head regions-ghA, ghB and ghC of human C1q bound to phospholipids on solid phase (Fig. 7A ) and in liposomes (Fig. 7B) . Comparisons between the relative binding of native C1q and recombinant globular heads to phospholipid-coated wells reveal that both native (Fig. 1 ) and recombinant proteins (Fig. 7A) bound PA, CL and PS, with weaker binding to PG and PI. There was no significant binding of the globular heads to PC. The recombinant globular heads bound well to CL-liposomes, and to a lesser extent, to PA-liposomes (Fig. 7B) , similar to native C1q (Fig. 2) . These results show that the globular heads of C1q, and not the collagen region, are responsible for interaction with anionic phospholipids (with the possible exception of the artifactual interaction with plate-bound PE). Furthermore, C1q was able to compete with the three individual globular heads for binding to CL (Fig. 8) . Therefore, the mode of binding of the globular head regions is similar to that seen in whole C1q. The three C-terminal regions of C1q, A, B and C chains, have been shown to interact differentially with heat-aggregated IgG and IgM, as well as three known C1q binding peptides, derived from HIV-1, HTLV-1 and β-amyloid (Kojouharova et al., 1998; Kishore and Reid, 2000) . It is notable that binding of C1q to β-amyloid fibrils, previously suggested to occur via the collagen region (A chain) (Jiang et al., 1994) has been shown to occur via the gC1q domain (Tacnet-Delorme et al., 2001) .
We found that 125 I-factor H (Fig. 1) bound strongly to the anionic phospholipids PA, CL, PG and PI. Binding to PS was weaker, and there was negligible binding to PE and PC. The binding profile is distinct from that of C1q. Using multilamellar liposomes, factor H clearly binds to CL, while binding to PA, PS, PG and PI is low. Surprisingly, there is some interaction with PE liposomes, although there was negligible interaction with solid-phase PE. Since both C1q and factor H bind to liposomes containing CL, and also PA, PS, PG and PI, it is likely that they bind in vivo to cell membranes in which these phospholipids are exposed at appropriate density. C1q binding is likely to promote complement activation while factor H binding might diminish complement activation. We addressed the question whether C1q and factor H can compete for binding to immobilised phospholipids. As evident from Fig. 3B , factor H and C1q do compete for binding to immobilised CL or CL-liposomes. β 2 -1 also inhibits C1q binding to immobilised CL (Fig. 3B) . β 2 -1 and factor H have similar binding properties to immobilised phospholipids (Yu et al., , 1997 Ferluga et al., 1998) . Inhibition of C1q binding to CL (on microtiter wells or in liposomes) was inhibited by 50% at a factor H/C1q molar ratio of about 1, indicating that avidity of binding is similar. Holme and colleagues (1992) suggested that factor H and C1q interact directly, so that the competition seen in Fig. 3B Hurwitz et al., 1995) . RHP was reported to bind C1q and to be closely related to factor H. There was disagreement as to whether RHP bound to C1q via the globular head, or via the collagen region (Easterbrook-Smith et al., 1992; Holme et al., 1992) , and also disagreement whether RHP was identical to factor H (Holme et al., 1992; Hurwitz et al., 1995) . We suggest that RHP may be a post-translationally modified form of factor H with tyrosine sulphation (Sim et al., 2008) . There are previous reports of two forms of factor H, Ф 1 and Ф 2 (Ripoche et al., 1988b) , with distinct properties, and Ф 2 , which is sulphated (Sim, R.B. and Lipscombe, R.J., unpublished) may correspond to RHP. However, our studies show that factor H from pooled normal sera does not bind C1q. It is possible, but not examined in our study, that Ф 2 (RHP) when deposited at appropriate density, may bind C1q. Interaction between serum and phospholipids resulted in antibody-independent activation of the classical pathway (Fig.  6 ). Since both C1q and factor H bind competitively to phospholipids, factor H is acting as a negative regulator of classical pathway activation. Factor H (and possibly also β 2 -1) regulates classical complement pathway activation by other non-immunoglobulin activators in a similar fashion. We have evidence for this regulatory effect of factor H with several other activators (Sim et al., 2008) and Blom and colleagues have also commented on this regulatory activity (Sjöberg et al., 2009 ). The effect of varying factor H:C1q molar ratio on classical pathway activation in serum (Fig. 9) shows clearly the regulation of the classical pathway by factor H.
When human serum is exposed to solid-phase CL at low ionic strength ( < 50 mM NaCl), IgG, β 2 -1 and factor H are the major proteins which bind to CL Ferluga et al., 1998) . Because of the high binding of IgG under these conditions, we examined whether immunoglobulin modifies binding of C1q to phospholipids at physiologic salt. Antiphospholipid antibodies are quite heterogenous and vary widely in quantity and specificity between different individuals. Normal individuals have low titers of antibodies against phospholipids and high levels are seen in patients with antiphospholipid syndrome (APS). Using purified immunoglobulin from pooled NHS, we were able to show that IgG (Fig. 5B) bound to all the immobilised phospholipids while IgA (Fig. 5A) and IgM (Fig. 5C ) also bound to all plate-bound phospholipids except PC. However, the quantity of immunoglobulin bound was very small (Table 1) . Not surprisingly, phospholipidbound IgG has small or negligible effect on C1q binding (Fig. 5E) given that only up to 1.4% of the surface area of the well is occupied by IgG. The area of the phospholipid-coated well was calculated from the radius and height of filling. The surface area occupied by one immunoglobulin molecule was calculated from the approximate hydrated radii of IgG, IgA and IgM (5 nm, 5 nm, 12 nm, respectively). IgM (Fig. 5F ) has also very little effect on C1q binding. There was a small anomaly with IgA (Fig. 5D) , which reduced C1q binding even though IgA binding occupies less than 0.5% of the surface area of the well. It is unlikely that steric interference could explain our observation. There was insignificant binding of purified immunoglobulins to phospholipid liposomes. These results show that in NHS at physiologic ionic strength, immunoglobulins do not interfere with C1q binding to phospholipids.
SDS-PAGE analysis of serum proteins binding to solidphase CL (Fig. 3A) revealed factor H and β 2 -1 as two major proteins interacting with CL. A low amount of C1q was also seen. Thus, C1q and factor H bind from whole serum, and C1q binds as C1 (since the serum used in the binding did not contain Ca 2+ chelators). The relative quantities of C1q and factor H bound are consistent with the competition between C1q and factor H seen in Fig. 3B . In serum, there is on average approximately 8-fold molar excess of factor H over C1q (considering the concentration of factor H as 200 μg/mL and of C1q as 80 μg/mL). Taking into account β 2 -1, which in this respect behaves like factor H, the molar excess of β 2 -1 and factor H over C1q is about 20:1. As shown in Fig. 9 , reducing the quantity of factor H relative to C1q stimulates classical pathway activation. Despite the competition for binding to phospholipids between factor H or β 2 -1 and C1q, anionic phospholipids, both solid-phase and as liposomes do activate the classical complement pathway (Fig. 6 ) when incubated with serum. All the anionic phospholipids (PA, CL, PS, PG and PI) on solid phase (Fig. 6A ) and in liposomes (Fig. 6C) were able to activate complement. Zwitterionic PE-coated on wells, but not in liposomes, was also able to activate complement which is consistent with the observed binding of C1q to well-coated PE (Fig. 1) , but not to PE liposomes (Fig. 2) . Immobilised phospholipids alone did not activate the alternative pathway (Fig. 6B ). These assays were done using IgG-depleted serum, and the results were consistent with direct binding of C1, and activation of C1 by the phospholipids. As suggested by Fig. 9 , binding of factor H and β 2 -1 diminishes the activation to the levels observed.
Measurable but very low binding (at saturation) of immunoglobulin on microtiter plates (Fig. 5, Table 1 ) was observed. Binding of immunoglobulin also had little effect on C1q binding (Fig. 5 ). Despite this, it was found that presaturating the immobilised phospholipids with IgG or IgM significantly increased complement consumption. In the case of pre-coating with IgM, complement consumption was increased by 50%-100% and a lesser effect was seen for IgG. IgA also had a small effect (Fig. 6A) . Precoating with IgG, but not with IgA or IgM, also produced a slight consumption of alternative complement pathway activity (Fig. 6B ). IgG F(ab')2 is known to activate the alternative complement pathway (Gadd and Reid, 1981) .
In classical complement pathway consumption ( Fig. 6A  and 6C ), the extent of consumption does not correlate closely with binding of purified C1q (Fig. 1 and 2 ). However, both factor H and β 2 -1 will modulate C1q (C1) binding from serum, so the extent of activation may be a function of C1, factor H and β 2 -1 binding. The complement consumption assays ( Fig.  6A and 6C ) were done at saturating concentrations of C1q and factor H (in serum) while the tests of isolated C1q and factor H binding to phospholipids ( Fig. 1 and 2) were done below saturation, so the ratios of bound C1q/factor H at saturation cannot be judged directly from Fig. 1 and Fig. 2 . The effect on complement consumption of saturating platebound phospholipids with immunoglobulin ( Fig. 6A) is surprising, since only a very small amount of immunoglobulin is bound. IgG and IgM appear to stimulate complement activation (consumption) but do not have profound effect on C1q binding (Fig. 5 ). There may be several variables which contribute to this effect: Okada et al. (1985) have suggested that C1 binds more strongly to IgG than does C1q, because of a secondary interaction between C1s and IgG Fc. Thus, IgG may have a bigger influence on C1 binding (from serum) than on binding of purified C1q. Another possible influence of immunoglobulins is in providing a suitable binding site for C4b. Dodds and Porter (1979) have shown that different C1q binding surfaces have different capacities for binding nascent C4b: for example antibody-antigen complexes fix C4b more efficiently than heat-aggregated IgG or Fc. The presence of bound immunoglobulin on the phospholipid surfaces may increase the amount of C4b2a, the classical complement pathway convertase formed.
In conclusion, this study has, for the first time, examined the interaction both of forward acting C1q and downregulatory factor H with phospholipids. C1q bound to solid-phase anionic phospholipids and in liposomes in an antibody-independent manner. The anionic phospholipids also activated complement via the classical complement pathway and immunoglobulin in normal serum has only small effects on C1q binding but has larger effects on subsequent activation of the classical complement pathway. However, factor H also binds to anionic phospholipids and acts as a direct downregulator of classical pathway activation. This activity is distinct from its well-explored role as a regulator of alternative pathway activation. This activity of factor H is likely to be important in preventing excessive (inflammatory) classical complement pathway activation by anionic phospholipids, such PS and CL, exposed on necrotic cell fragments (e.g., mitochondria (Peitsch et al., 1988) ) or on cells altered by bacterial and spider venom sphingomyelinases (Tambourgi et al., 2002 (Tambourgi et al., , 2007 . PS and CL are exposed on apoptotic cell surfaces (Martin et al., 1995; Sorice et al., 2000) , although they may not be the major binding sites for C1q and factor H on these cells.
MATERIALS AND METHODS
Chemicals and reagents
Inorganic salts were from Sigma (Poole, Dorset, UK), Fisons (Loughborough, Leicester, UK) or Merck/BDH Laboratory Supplies (Poole, Dorset, UK). Dithiothreitol (DTT), iodoacetamide, N, N, N′, N′-tetramethylethylenediamine (TEMED), EDTA, polyoxyethylenesorbitan monolaurate (Tween 20), glucose, urea, (1,3,4,6)-tetrachloro-3a, 6a-diphenylglycoluril (Iodogen), Coomassie Brilliant Blue R250, pnitrophenol phosphate, SDS polyacrylamide gel electrophoresis molecular weight markers and ovalbumin were from Sigma. Low molecular weight range prestained SDS-PAGE markers were from Gibco BRL (Gaithersburg, MD, USA). Acrylamide-bisacrylamide stock mixture for SDS-PAGE (protogel: 30% w/v acrylamide and 0.8% bisacrylamide) was from National Diagnostics (Hessle, Yorks, UK).
Buffers
The following buffers were used: Veronal buffers (VB, 5 mM sodium barbital, 142 mM NaCl, pH 7.4; VB 2+ , 5 mM sodium barbital, 142 mM NaCl, 0.15 mM CaCl 2, 0.5 mM MgCl 2 , pH 7.4; DGVB 2+ , dextrose gelatin veronal buffer (2.5 mM sodium barbital, 71 mM NaCl, 0.15 mM CaCl 2, 0.5 mM MgCl 2, 2.5% w/v glucose, 0.1% w/v gelatin, pH 7.4); DGVBMg-EGTA (7 mM MgCl 2 , 10 mM EGTA, 21% v/v DGVB, 3.1% w/v D-glucose) and SDS-PAGE sample buffer (0.2 M Tris-HCl, 8 M urea, 2% w/v SDS, pH 8.0). PBS was Dulbecco's phosphate-buffered saline (137 mM NaCl, 2.6 mM KCl, 8.2 mM Na 2 HPO 4 and 1.5 mM KH 2 PO 4 , pH 7.4) prepared from tablets (Oxoid: Unipath Ltd, Basingstoke, Hants, UK).
Phospholipids and antibodies
The phospholipids-PA (dipalmitoylphosphatidic acid), CL (bovine heart cardiolipin), PS (dipalmitoylphosphatidylserine), PG (dipalmitoylphosphatidylglycerol), PI (bovine liver phosphatidylinositol), PE (dimyristoylphosphatidylethanolamine) or PC (dipalmitoylphosphatidylcholine) were from Sigma as was cholesterol (CHOL). Heavychain-specific affinity purified secondary antibody conjugates (goat anti-human IgA alkaline phosphatase (A3063), goat anti-human IgG alkaline phosphatase (A3187), goat anti-human IgM alkaline phosphatase (A3437) and rabbit anti-mouse IgG alkaline phosphatase (A4312)) were from Sigma.
Purified proteins and antibodies
C1q was purified from pooled human serum using affinity chromatography on IgG-Sepharose. Briefly, 200 mL human plasma was made 5 mM EDTA by addition of 200 mM sodium EDTA, pH 7.4 and chilled to 0°C. IgG-Sepharose (20 mL with 20 mg of nonimmune human IgG bound/mL was added to the plasma and incubated for 45 min on ice with occasional gentle stirring. IgG-Sepharose was washed rapidly on a scintered glass funnel with ice-cold 10 mM HEPES, 140 mM NaCl, 0.5 mM EDTA, pH 7.4, until the OD 280 of the wash was < 0.04. IgGSepharose was rapidly packed into a 2.5 cm diameter column, and bound C1q was eluted with a high-salt pH 11.2 buffer (e.g., 50 mM CAPS, 1 M NaCl, 5 mM EDTA). The pH of fractions was lowered by addition of 0.3 vol of 1 M sodium phosphate, pH 7, and fractions were analyzed by SDS-PAGE. Human factor H, purified by monoclonal antibody affinity chromatography was provided by B.E. Moffatt, MRC Immunochemistry Unit, Oxford. Human β 2 glycoprotein-1 (β 2 -1), also known as apolipoprotein H, was purified as described by Williams and Sim (1993) . Human immunoglobulins (IgA, IgG and IgM) were purified from human serum pooled from at least 20 donors using published methods (Johnstone and Thorpe, 1987) . The globular head regions of A (ghA), B (ghB) and C (ghC) chains were expressed in E. coli as fusions to maltose binding protein (MBP) and purified as described previously ). Fraker and Speck, 1978) Centrifuge tubes (1.7 mL) were coated with iodogen by evaporation of chloroform from 2 mg/mL iodogen in chloroform. Into iodogen-coated tubes (200 μg iodogen/tube) were placed 1 mCi of Na 125 I (GE Healthcare, Little Chalfont, Bucks, UK), 20 μL 1 M potassium phosphate buffer pH 7.4 and 50 μg of protein in 500 μL of PBS + 0.5 mM EDTA (PBS-EDTA). Tubes were incubated on ice for 5 min after which the solution was desalted on a PD-10 column (GE Healthcare) with PBS-EDTA to remove unbound Na 125 I. Typical specific activities obtained were 1.07 × 10 7 cpm/μg for IgA, 1.14 × 10 7 cpm/μg for IgG, 1.5 × 10 5 cpm/μg for IgM and 1.1 × 10 7 cpm/μg for factor H (counting efficiency of 70%).
Radioiodination of proteins
Iodination of immunoglobulin and factor H (
Iodination of C1q, ghA, ghB and ghC These proteins are very sensitive to oxidation and were iodinated under milder conditions. CPG-10 (BDH Chemicals, Poole, UK) controlled pore glass beads (100 mg) was mixed with 1 mL of chloroform solution containing iodogen (200 μg iodogen/mL) and incubated at RT for 5 min before the beads were dried under a stream of oxygen-free nitrogen. 10 mg of Iodogen-coated CPG-10 glass beads (20 μg iodogen/10 mg beads) were mixed with 500 μL of PBS-EDTA, 20 μL 1 M potassium phosphate buffer pH 7.4, 0.3 mCi of Na 125 I and 50 μg of protein and incubated on ice for 5 min after which the mix was transferred to a de-salting column to remove unbound Na 125 I. Typical specific activities were 2.8-9.2 × 10 5 cpm/μg for C1q, 1.7 × 10 6 cpm/μg for ghA, 1.5 × 10 6 cpm/μg for ghB and 1.9 × 10 6 cpm/μg for ghC with a counting efficiency of 70%. For some experiments, radioiodinated components were diluted with unlabelled material to reduce the specific activity.
Preparation of sera
Normal human serum (NHS) was made from plasma pooled from at least 20 donors (HD Supplies, Aylesbury, UK) which was recalcified by adding 1 M CaCl 2 to a final concentration of 16mM and left to clot overnight at 4°C. The serum was collected by filtering through muslin. IgG-depleted pooled human serum was made by passing 2 mL NHS through a 1 mL HiTrap protein G column (GE Healthcare) equilibrated with start buffer (20 mM potassium phosphate, pH 7.4). The sample was eluted with the start buffer at a rate of 1 mL/min. Serum depleted of C1q was made by dialysing NHS overnight against running buffer (20 mM Tris-HCl, 100 mM NaCl, 0.5 mM EDTA pH 7.4), chilling to 0°C, loading onto a Sepharose non-immune IgG column (20 mg IgG/mL) at 0°C, and eluting with ice-cold running buffer. The flow-through was tested for the absence of C1q activity by hemolytic assay. Serial dilutions in DGVB 2+ of the depleted serum (100 μL) were incubated with 1 × 10 7 EA cells (100 μL in DGVB
2+
) at 37°C for 30 min. The EA cells were washed once by centrifugation, resuspended in DGVB 2+ and incubated with 110 dilution of a commercial C1q-depleted serum (Sigma) in DGVB 2+ for 1 h. Lysis of EA was then measured. C1q-depleted serum was then further depleted of factor H as described by Schneider et al. (2006) . Factor H depletion was measured by ELISA (Schneider et al., 2006) .
SDS-PAGE
SDS-PAGE was carried out according to Laemmli (1970) . Sample preparation and Coomassie Blue staining was done as by Fairbanks et al. (1971) .
Solid phase binding assays
Preparation of phospholipid-coated wells
Microtiter wells Nunc, Kamstrup, Denmark) were coated with 100 μL/well of 50 μg/mL of one of the phospholipids PA, CL, PS, PG, PI, PE or PC in a 2:1 (v/v) solution of methanol/ chloroform. Solvents were evaporated in air overnight at 4°C. Wells were subsequently blocked with 200 μL of 10 mM potassium phosphate buffer, pH 7.4, and 0.5 mg/mL ovalbumin for 2 h at RT.
Preparation of protein-coated wells
Microtiter wells (Maxisorp™, Nunc) were coated with 5 μg of the sample protein (C1q or factor H) per well in 100 μL of coating buffer (0.1 M NaHCO 3 , pH 9.6) at RT for 1 h. The wells were then washed three times with PBS containing 0.1% (v/v) Tween-20 (PBS-Tween) and blocked with 200 μL of PBS-Tween for 1 h at RT. Immunoglobulin binding to phospholipid-coated wells Dilutions of purified immunoglobulin (IgA, IgG or IgM) were placed in phospholipid-coated wells for 1 h at RT in PBS-EDTA. Following three washes with PBS-EDTA, the bound immunoglobulins were probed with affinity purified anti-immunoglobulin alkaline phosphatase conjugate in PBS-EDTA (heavy-chain specific) for 1 h at RT. After three washes in PBS-EDTA, color was developed using para-nitrophenyl phosphate (pNPP; Sigma) as a substrate, and then read at A 405 . Controls were phospholipid-coated wells incubated with PBS-0.5 mM EDTA without immunoglobulin.
Saturation binding of immunoglobulin to phospholipids
A fixed amount of 125 I-immunoglobulin (10,000-50,000 cpm) (IgA, IgG or IgM) was added together with serial dilutions of unlabelled immunoglobulin (0-20 μg) in PBS-EDTA to a final volume of 100 μL and loaded onto phospholipid-coated wells (5 μg phospholipid/well), incubated for 1 h at RT and washed three times with PBS-EDTA. Quantitation of bound -0.5 mg/mL ovalbumin was incubated in factor H coated wells for 1 h at RT. The wells were washed three times with VB 2+ and bound 125 I-C1q was detected as before. Purified C1q was coated on microtiter plate wells as described above. Factor H in PBS-Tween (5 μg/well) was incubated for 1 h at RT with the C1q coated wells. Mouse monoclonal anti-human factor H (1 μg/mL; MRC OX23) (Sim et al., 1983) and 1:7500 dilution of affinity purified rabbit anti-mouse IgG conjugated alkaline phosphatase secondary antibody were used to detect factor H. Wells coated directly with factor H were used as a positive control.
Analysis by SDS-PAGE of human serum proteins bound to CL-coated wells Wells of a 24-well tissue culture plate; NUNC) were coated with CL (2 mL of 50 μg/mL in 2:1 (v/v) solution of methanol/chloroform per well). Solvents were evaporated in air at 4°C. NHS (1 mL) was diluted to 2 mL with 10 mM potassium phosphate, pH 7.4, placed in the wells and incubated at RT for 2 h. Wells were washed three times with 10 mM potassium phosphate, pH 7.4 and bound proteins were eluted with 100 μL of SDS-PAGE sample buffer (Fairbanks et al., 1971) and further analyzed by SDS-PAGE. I-ghC was measured as before. Ovalbumin in place of C1q was used as a control.
Liposome binding assays
Preparation of liposomes
Multilamellar liposomes were prepared according to established methods (New, 1990) . The standard liposome preparations used in binding studies and in the functional complement activation studies were composed of 25 molar percent PC, 45 molar percent CHOL with 30 molar percent of one of the following phospholipids: PA, CL, PS, PG, PI or PE. PC liposomes contained only 55 molar percent PC and 45 molar percent CHOL. The liposome suspensions were 100 μg/mL total lipid in VB
2+
. Quantitative determination of total phospholipids was performed using the Stewart (1980) -1 mg/mL ovalbumin) and incubated for 1 h at RT. The tubes were then spun at 10,000 g in a microfuge for 10 min and the supernatant removed. The pellet was washed once with 300 μL of VB 2+ and spun again as before. After removing the supernatant, the pellet was counted in a gamma counter. I-ghC and binding assessed as described above for C1q and factor H.
Complement consumption assays
Preparation of sensitized sheep erythrocytes (EA) (Whaley and North, 1997) Sheep blood in Alsevers solution (TCS Biosciences, Bucks, UK) was washed thrice in PBS before re-suspending the erythrocytes in DGVB
2+
. Twenty milliliters of sheep erythrocytes (0.5 × 10 9 /mL) was then incubated with 10 μL of antiserum (rabbit anti-sheep hemolytic serum (C12HSA, Serotec, Kidlington, UK) for 1 h at 37°C before washing three times with DGVB 2+ .
Preparation of rabbit erythrocytes (Whaley and North, 1997) Rabbit erythrocytes were prepared from rabbit blood in Alsever's solution (TCS Biosciences) by washing rabbit erythrocytes three times in PBS before re-suspending in DGVB 2+ .
Assay of total complement consumption by phospholipid-coated wells in the presence or absence of immunoglobulin To examine complement consumption by phospholipids or phospholipid-immunoglobulin complexes, saturating amounts of immunoglobulin in a final volume of 100 μL were incubated in each phospholipidcoated well for 1 h at RT. Wells were washed 3 times with DGVB 2+ .
One hundred microlitres of IgG-depleted pooled NHS diluted 1:1 with DGVB 2+ was added to wells coated with phospholipids only, or phospholipids plus immunoglobulin and incubated at 37°C for 1 h. The incubated serum was serially diluted with DGVB 2+ and 100 μL of each dilution was further incubated for 1 h at 37°C with 1 × 10 7 (100 μL) sensitized EA to assess the remaining complement activity of the serum. The microtiter plates were then centrifuged at 2500 rpm for 15 min before collecting the supernatant and reading the absorbance at 414 nm. This assay measures the extent of complement consumption occurring during incubation with phospholipidcoated or phospholipid-immunoglobulin-coated wells by assessing the ability of the incubated serum to lyse EA. Serum incubated in wells without phospholipids but blocked with VB 2+ -0.5 mg/mL ovalbumin was used as a control.
Assay of total complement consumption by phospholipid liposomes
Pooled NHS (200 μL) was diluted with 200 μL of phospholipid liposomes (100 μg/mL) in DGVB 2+ and incubated for 1 h at 37°C.
After centrifugation (10,000 g for 10 min), the supernatant was assessed for consumption of complement as described above. Controls were serum diluted with DGVB 2+ containing no phospholipid liposomes.
Assay of alternative pathway complement consumption by phospholipid-coated wells in the presence or absence of immunoglobulin (Whaley and North, 1997) To measure whether phospholipid surfaces or phospholipid coated with immunoglobulin (see above) can activate the alternative pathway, a 1:5 dilution of serum in DGVBMg-EGTA (7 mM MgCl 2 , 10 mM EGTA, 21% v/v DGVB, 3.1% w/v D-glucose) was incubated with the surface for 1 h at 37°C. The serum was then serially diluted with DGVBMg-EGTA and 100 μL of the serum dilutions incubated for 1 h at 37°C with 100 μL of rabbit erythrocytes at 1 × 10 8 /mL in microtiter wells. Subsequent steps were performed as above for assessment of classical pathway complement activity.
Inhibition of classical pathway activation by factor H To determine the effect of factor H on C1q-initiated classical pathway activation, serum samples in which the C1q:factor H molar ratio had been adjusted to a range of values were incubated with a complement activator (CL-coated microtiter-plate wells), then the deposition of C4b on the wells was measured.
C1q and factor H-depleted serum (completely C1q deficient, but only 75% depleted of factor H) was repleted with various molar ratios of C1q and factor H and incubated in CL-coated wells for 1 h at 37°C. Repletion was done by adding a fixed quantity of C1q and a variable quantity of factor H. This was done by mixing 13 µL of depleted serum with 87 µL of VB 2+ containing 0.9 µg of C1q and 0.9-21.6 µg of factor H. The addition of C1q restored the serum to a C1q concentration equivalent to 69ug per ml of undiluted serum. The CL-coated wells were washed 3 times in VB 2+ and C4b fixation on the wells was measured by ELISA as described by Presanis et al. (2004) .
